Total Payments
$13,821
2024 Payments
$1,611
Companies
34
Transactions
192
Medicare Patients
10,256
Medicare Billing
$986,892
Payment Breakdown by Category
Research$8,262 (59.8%)
Food & Beverage$5,399 (39.1%)
Education$159.94 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,262 | 1 | 59.8% |
| Food and Beverage | $5,399 | 189 | 39.1% |
| Education | $159.94 | 2 | 1.2% |
Payments by Type
Research
$8,262
1 transactions
General
$5,559
191 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $8,262 | 1 | $0 (2023) |
| GENZYME CORPORATION | $1,019 | 29 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $834.78 | 27 | $0 (2024) |
| Amgen Inc. | $573.52 | 7 | $0 (2024) |
| Incyte Corporation | $539.28 | 29 | $0 (2024) |
| PFIZER INC. | $446.56 | 29 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $378.89 | 1 | $0 (2021) |
| ABBVIE INC. | $295.12 | 5 | $0 (2024) |
| LEO Pharma Inc. | $222.40 | 9 | $0 (2024) |
| Dermavant Sciences, Inc. | $152.40 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,611 | 49 | Amgen Inc. ($298.60) |
| 2023 | $9,646 | 50 | Eli Lilly and Company ($8,262) |
| 2022 | $843.19 | 35 | GENZYME CORPORATION ($230.68) |
| 2021 | $790.28 | 20 | MERZ NORTH AMERICA, INC. ($378.89) |
| 2020 | $159.91 | 7 | Janssen Biotech, Inc. ($48.86) |
| 2019 | $388.74 | 9 | Amgen Inc. ($231.52) |
| 2018 | $166.79 | 9 | Novartis Pharmaceuticals Corporation ($63.19) |
| 2017 | $215.50 | 13 | Galderma Laboratories, L.P. ($53.13) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 2 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/06/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Dermatology | ||||||
| 04/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.51 | General |
| Category: Immunology | ||||||
| 04/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: IMMUNOLOGY | ||||||
| 04/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $46.68 | General |
| Category: Immunology | ||||||
| 04/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.54 | General |
| Category: Dermatology | ||||||
| 03/26/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: DERMATOLOGY | ||||||
| 03/26/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: DERMATOLOGY | ||||||
| 03/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.45 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: DERMATOLOGY | ||||||
| 03/15/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $15.16 | General |
| Category: Dermatology | ||||||
| 03/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $142.53 | General |
| Category: Inflammation | ||||||
| 03/08/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $134.02 | General |
| Category: Inflammation | ||||||
| 03/07/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $63.51 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 03/05/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: DERMATOLOGY | ||||||
| 03/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $49.59 | General |
| Category: Immunology | ||||||
| 02/07/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: DERMATOLOGY | ||||||
| 02/07/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $1.14 | General |
| Category: DERMATOLOGY | ||||||
| 02/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.86 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $45.83 | General |
| Category: Immunology | ||||||
| 01/12/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: DERMATOLOGY | ||||||
| 01/10/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: DERMATOLOGY | ||||||
| 01/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.43 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/27/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.50 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $8,262 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 2,953 | 3,964 | $526,620 | $293,611 |
| 2022 | 21 | 2,755 | 3,630 | $477,380 | $266,256 |
| 2021 | 25 | 2,618 | 3,507 | $457,365 | $262,114 |
| 2020 | 19 | 1,930 | 2,532 | $316,960 | $164,911 |
Total Patients
10,256
Total Services
13,633
Medicare Billing
$986,892
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 802 | 1,376 | $169,765 | $103,393 | 60.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 650 | 650 | $92,695 | $56,629 | 61.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 407 | 443 | $67,585 | $39,115 | 57.9% |
| 11106 | Incision biopsy, first skin growth | Office | 2023 | 97 | 115 | $24,525 | $15,811 | 64.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 213 | 318 | $29,685 | $13,319 | 44.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 163 | 213 | $32,500 | $11,173 | 34.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 132 | 179 | $16,490 | $8,134 | 49.3% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 26 | 28 | $10,660 | $6,340 | 59.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 24 | 31 | $9,655 | $5,767 | 59.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 41 | 50 | $8,135 | $4,836 | 59.5% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 16 | 16 | $5,080 | $3,395 | 66.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 30 | 30 | $5,480 | $3,367 | 61.4% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 89 | 105 | $14,075 | $3,262 | 23.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 18 | 20 | $5,010 | $3,032 | 60.5% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 18 | 19 | $4,115 | $2,629 | 63.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 36 | 37 | $5,640 | $2,560 | 45.4% |
| 11641 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 12 | 13 | $4,050 | $2,021 | 49.9% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 14 | 31 | $2,970 | $1,855 | 62.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 16 | $2,465 | $1,768 | 71.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 24 | 24 | $3,640 | $1,660 | 45.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 66 | 183 | $5,945 | $1,088 | 18.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 18 | 18 | $2,060 | $868.43 | 42.2% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 17 | 19 | $1,645 | $793.12 | 48.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 16 | $1,305 | $661.44 | 50.7% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 13 | 14 | $1,445 | $132.30 | 9.2% |
About Dr. Sid Danesh, M.D
Dr. Sid Danesh, M.D is a Dermatology healthcare provider based in San Gabriel, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063447134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sid Danesh, M.D has received a total of $13,821 in payments from pharmaceutical and medical device companies, with $1,611 received in 2024. These payments were reported across 192 transactions from 34 companies. The most common payment nature is "" ($8,262).
As a Medicare-enrolled provider, Danesh has provided services to 10,256 Medicare beneficiaries, totaling 13,633 services with total Medicare billing of $986,892. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location San Gabriel, CA
- Active Since 07/11/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063447134
Products in Payments
- TALTZ (Drug) $8,365
- DUPIXENT (Biological) $1,837
- OPZELURA (Drug) $444.29
- EUCRISA (Drug) $349.11
- Otezla (Drug) $298.60
- Enbrel (Biological) $274.92
- RINVOQ (Biological) $193.85
- VTAMA (Drug) $152.40
- COSENTYX (Biological) $140.74
- ADBRY (Biological) $131.83
- TREMFYA (Drug) $108.87
- SKYRIZI (Biological) $101.27
- CIBINQO (Drug) $97.45
- ENSTILAR (Drug) $90.57
- DAXXIFY (Drug) $63.51
- Mupirocin Cream (Drug) $56.00
- REMICADE (Biological) $48.86
- CELLEX (Device) $40.10
- Sotyktu (Drug) $35.00
- DORYX (Drug) $31.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.